A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

Eligibility Criteria

• * Participants with established ASCVD history of one or more of the following
• 1. Prior Myocardial infarction (MI) (\>60 days from index event) or coronary revascularization procedure like coronary stenting or Coronary artery bypass graft (CABG)
• 2. Prior ischemic stroke (\>60 days from index event)
• 3. Symptomatic Peripheral Arterial Disease
• * Chronic kidney disease defined as eGlomular filtration rate (eGFR) ≥ 30 to \< 60 mL/min/1.73 m2
• * Serum hsCRP \> 2 mg/L
• * Body mass index ≥ 18 to ≤ 45 kg/m2
• * All females must have a negative pregnancy test at the Screening Visit and at the randomization visit
• 1. Sexually active male participants with partner of childbearing potential must adhere to the contraception methods
• 2. Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception
• 3. Females of non-childbearing potential must be confirmed at the Screening visit
• * History of malignancy within the last 5 years
• * History of MI, coronary revascularization, stroke or revascularization for peripheral arterial disease in the 60 days prior to Screening
• * Active systemic infection within 30 days
• * Clinically significant active and chronic infections within 60 days prior to randomization
• * Clinically significant recurrent infection (≥ 2× during the last 12-month period).
• * Renal transplant participants, participants on dialysis, and those with a history of acute kidney injury in the past 12 month